Back to top
more

ACADIA Pharmaceuticals (ACAD)

(Real Time Quote from BATS)

$18.49 USD

18.49
191,113

+0.83 (4.70%)

Updated Nov 11, 2024 10:46 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Glaxo's Nucala Label Expansion Application Gets FDA Approval

GlaxoSmithKline's (GSK) application to include treatment of eosinophilic granulomatosis with polyangiitis in Nucala's label was approved by the FDA.

    Proteostasis Stock Surges on Positive Data From CF Studies

    Proteostasis (PTI) stock skyrockets on positive results from early and mid-stage studies on its cystic fibrosis pipeline candidates.

      Lilly Reports Mixed Results from Late-Stage Cyramza Study

      Lilly's (LLY) gastric cancer drug, Cyramza, meets primary endpoint of progression free survival in a phase III study in first-line advanced gastric cancer patients. However, it failed to improve overall survival.

        Medicines Company to Sell Infectious Disease Unit to Melinta

        The Medicine Company (MDCO) has signed an agreement with Melinta to sell its infectious disease unit in a cash and stock transaction.

          Spectrum Doubles in 3 Months: What's Driving the Rally?

          Spectrum (SPPI) focuses on developing pipeline candidates. The stock doubled in the last three months mainly on encouraging data from poziotinib study.

            What's in the Cards for Adverum (ADVM) This Earnings Season?

            Adverum Biotechnologies (ADVM) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.

              Is a Beat in the Cards for Perrigo (PRGO) in Q3 Earnings?

              Perrigo's (PRGO) product acquisitions and new product launches in the Rx segment might boost sales in the coming quarters.

                Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store? (revised)

                Horizon Pharma???s shares have declined 12% in the year so far, underperforming the industry???s gain of 0.9%.

                  Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store?

                  Horzion Pharma's (HZNP) primary care business is under pressure and we expect earnings to disappoint in the third quarter.

                    What to Expect from Keryx (KERX) This Earnings Season?

                    Keryx (KERX) will focus on the label expansion of its only approved drug, Auryxia, during the third-quarter 2017 earnings call.

                      Is ACADIA (ACAD) Likely to Beat Earnings Estimates in Q3?

                      ACADIA Pharmaceuticals' (ACAD) antipsychotic drug, Nuplazid, is expected to record strong sales in the third quarter despite increased prices backed by higher demand.

                        Will Endocyte (ECYT) Disappoint This Earnings Season?

                        Endocyte (ECYT) plans to focus on its most promising programs like CAR T-cell small-molecule drug conjugates (SMDC) adaptor platform and its pipeline candidate EC2629 in Q3.

                          Jazz Pharmaceuticals (JAZZ) Q3 Earnings: A Beat in Store?

                          Jazz Pharmaceuticals' (JAZZ) lead drug, Xyrem, is likely to deliver a strong performance in Q3, thanks to label expansion efforts. Also, other products look promising to lead to an earnings beat.

                            Is a Beat in the Cards for Mylan (MYL) This Earnings Season?

                            Mylan N.V. (MYL) is likely to beat results when it reports third-quarter results next week driven by newly launched generics.

                              What's in the Cards for Prothena (PRTA) in Q3 Earnings?

                              Investors focus should remain on pipeline updates when Prothena Corporation (PRTA) reports third-quarter results as it has no approved product in its portfolio.

                                What's in the Cards for Arena (ARNA) This Earnings Season?

                                Although Belviq, the only approved product in Arena's (ARNA) portfolio, has an unimpressive show so far, the company's efforts to improve the drug's performance might drive the stock in Q3.

                                  Ball Corporation (BLL) to Post Q3 Earnings: What to Expect?

                                  Ball Corporation's (BLL) Q3 results are likely to benefit from improvement in food and aerosol business. However, additional depreciation and non-steel related amortization expense are headwinds.

                                    Is a Beat in Store for Zoetis (ZTS) This Earnings Season?

                                    Zoetis' (ZTS) top line is expected to be driven by newly launched Apoquel, Simparica and Cytopoint. The approvals of Clavamox and Nexvet are expected to boost sales further.

                                      Valeant Reports Positive Results on Psoriasis Drug Siliq

                                      Valeant Pharmaceuticals International, Inc. (VRX) announced encouraging results from the long-term phase III extension study, AMAGINE-2 on psoriasis drug Siliq.

                                        Lilly's Verzenio Gets Priority Review in First-Line Setting

                                        Eli Lilly and Company (LLY) announced that the FDA has granted priority review to its new drug application for Verzenio (abemaciclib) for the first-line treatment of advanced breast cancer.

                                          Here's Why Intercept (ICPT) Stock Lost 37% So Far in 2017

                                          Shares of Intercept Pharmaceuticals (ICPT) have plunged 37% in the year so far due to safety issues regarding approved drug Ocaliva.

                                            Allergan's Uterine Fibroids Candidate's NDA Accepted by FDA

                                            Allergan plc (AGN) announced that the FDA has accepted the new drug application (NDA) for ulipristal acetate, for the treatment of abnormal uterine bleeding in women with uterine fibroids.

                                              Mallinckrodt to Begin Sarcoidosis Study on Acthar Gel

                                              Mallinckrodt plc (MNK) announced that it will initiate a new phase IV study on H.P. Acthar Gel as a therapy option in patients with symptomatic sarcoidosis.

                                                Why Should You Invest in Novo Nordisk (NVO) Stock Right Now

                                                Novo Nordisk (NVO) has a strong presence in the Diabetes care market and the current quarter has seen some events happening for the company that bode well for its growth.

                                                  AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation

                                                  AstraZeneca (AZN) obtained Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer.